FENNEC PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On March 24, 2022, Fennec Pharmaceuticals Inc. issued a news release announcing it has completed its resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (sodium thiosulfate anhydrous injection) for intravenous use. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

  (d) Exhibits.




Exhibit No.      Description

  Exhibit 99.1     Press Release dated March 24, 2022

Exhibit 104 Cover Page Interactive Data File (embedded as Inline XBRL document)

© Edgar Online, source Glimpses